share_log

Sera Prognostics | 10-Q: Q3 2024 Earnings Report

Sera Prognostics | 10-Q: Q3 2024 Earnings Report

Sera Prognostics | 10-Q:2024財年三季報
美股SEC公告 ·  11:32

牛牛AI助理已提取核心訊息

Sera Prognostics, a women's health company, reported a net loss of $7.9 million for Q3 2024, compared to a net loss of $7.2 million for Q3 2023. For the nine months ended September 30, 2024, the net loss was $24.3 million, a decrease from $28.3 million in the same period of 2023. Revenue for Q3 2024 was $29 thousand, down from $42 thousand in Q3 2023, while revenue for the nine-month period was $53 thousand, a decrease from $265 thousand in the previous year. Operating expenses for Q3 2024 totaled $8.891 million, up from $8.226 million in Q3 2023. The company has taken steps to reduce annual operating expenses and believes its cash runway is sufficient to operate into 2027. Sera Prognostics' business development has been focused on its PreTRM test, a blood-based biomarker test for predicting preterm birth risk. The company announced...Show More
Sera Prognostics, a women's health company, reported a net loss of $7.9 million for Q3 2024, compared to a net loss of $7.2 million for Q3 2023. For the nine months ended September 30, 2024, the net loss was $24.3 million, a decrease from $28.3 million in the same period of 2023. Revenue for Q3 2024 was $29 thousand, down from $42 thousand in Q3 2023, while revenue for the nine-month period was $53 thousand, a decrease from $265 thousand in the previous year. Operating expenses for Q3 2024 totaled $8.891 million, up from $8.226 million in Q3 2023. The company has taken steps to reduce annual operating expenses and believes its cash runway is sufficient to operate into 2027. Sera Prognostics' business development has been focused on its PreTRM test, a blood-based biomarker test for predicting preterm birth risk. The company announced positive results from the AVERT PRETERM TRIAL and the PRIME study, which demonstrated the test's efficacy and potential to reduce healthcare costs. Sera Prognostics is seeking publication of the PRIME study results and plans to launch real-world evidence implementation programs in late 2024 or early 2025. The company's future plans include expanding market adoption of the PreTRM test, developing additional biomarker tests, and improving test accessibility through whole-blood collection technologies.
女性健康公司Sera Prognostics報告,2024年第三季度淨虧損爲790萬美元,較2023年第三季度720萬美元的淨虧損有所增加。截至2024年9月30日的九個月淨虧損爲2430萬美元,較2023年同期的2830萬美元有所減少。2024年第三季度營業收入爲2.9萬美元,較2023年第三季度的4.2萬美元下降,而九個月期間的營業收入爲5.3萬美元,較上年的26.5萬美元有所減少。2024年第三季度的營業費用總額爲889.1萬美元,較2023年第三季度的822.6萬美元有所提升。公司已經採取措施來減少年度營業費用,並認爲其現金儲備足以維持至2027年。Sera Prognostics的業...展開全部
女性健康公司Sera Prognostics報告,2024年第三季度淨虧損爲790萬美元,較2023年第三季度720萬美元的淨虧損有所增加。截至2024年9月30日的九個月淨虧損爲2430萬美元,較2023年同期的2830萬美元有所減少。2024年第三季度營業收入爲2.9萬美元,較2023年第三季度的4.2萬美元下降,而九個月期間的營業收入爲5.3萬美元,較上年的26.5萬美元有所減少。2024年第三季度的營業費用總額爲889.1萬美元,較2023年第三季度的822.6萬美元有所提升。公司已經採取措施來減少年度營業費用,並認爲其現金儲備足以維持至2027年。Sera Prognostics的業務發展主要聚焦於其PreTRm測試,一種基於血液的生物標誌物測試,用於預測早產風險。公司宣佈了來自AVERt PRETERm TRIAL和PRIME研究的積極結果,證明了該測試的有效性和降低醫療成本的潛力。Sera Prognostics正在尋求發表PRIME研究結果,並計劃在2024年底或2025年初推出真實世界證據實施計劃。公司未來的計劃包括擴大PreTRm測試的市場採用率,開發額外的生物標誌物測試,並通過全血採集技術改善測試的可及性。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。